시장보고서
상품코드
1299828

세계의 암 치료용 생물학적 제제 시장(2023-2033년)

Cancer Biologics Market Report 2023-2033

발행일: | 리서치사: Visiongain Reports Ltd. | 페이지 정보: 영문 308 Pages | 배송안내 : 1-2일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 암 치료용 생물학적 제제 시장 규모는 2023년 1,159억 달러로 추정되며, 2023년부터 2033년까지 9.1%의 CAGR을 나타낼 것으로 예상됩니다. 노인 인구 증가는 시장 성장을 가속할 수 있습니다. 그러나 암 치료의 부작용에 대한 환자들의 인식이 높아지면서 시장 성장을 억제할 것으로 보입니다.

이 보고서는 세계의 암 치료용 생물학적 제제(Cancer Biologics) 시장에 대해 조사했으며, 시장 개요, 시장 분석, 기업 프로파일 등의 종합적인 정보를 제공합니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

  • 주요 조사 결과
  • 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회
  • COVID-19의 영향 분석
  • Porter의 Five Forces 분석
    • 공급 기업의 교섭력
    • 바이어의 교섭력
    • 경쟁 기업간 경쟁 관계
    • 대체품의 위협
    • 신규 진출업체의 위협
  • PEST 분석

제4장 암치료용 생물학적 제제 시장 분석 : 제품별

  • 주요 조사 결과
  • 제품 부문 : 시장의 매력 지수
  • 암치료용 생물학적 제제 시장 규모 추정과 예측 : 제품별
  • 단클론항체
    • Naked Monoclonal Antibodies
    • Conjugated Monoclonal Antibodies
    • Bispecific Monoclonal Antibodies
  • 백신
    • 예방용 백신
    • 치료용 백신
  • 암 성장 차단제
    • Tyrosine kinase Inhibitors (TKI)
    • Proteasome Inhibitors (PI)
    • mTOR Inhibitors
  • 혈액세포 성장인자
    • Lenograstim
    • Filgrastim
  • 사이토카인
    • Interferons
    • Interleukins

제5장 암치료용 생물학적 제제 시장 분석 : 용도별

  • 주요 조사 결과
  • 용도 부문 : 시장의 매력 지수
  • 암치료용 생물학적 제제 시장 규모 추정과 예측 : 용도별
  • 비소세포 폐암
  • 전립선암
  • 유방암
  • 급성 골수성 백혈병
  • 림프종
  • 다발성 골수종
  • 난소암
  • 결장직장암
  • 위암
  • 기타

제6장 암치료용 생물학적 제제 시장 분석 : 투여 채널별

  • 주요 조사 결과
  • 투여 채널 부문 : 시장의 매력 지수
  • 암치료용 생물학적 제제 시장 규모 추정과 예측 : 투여 채널별
  • 경구
  • 주사

제7장 암치료용 생물학적 제제 시장 분석 : 지역별

  • 주요 조사 결과
  • 지역 시장 규모 추정과 예측

제8장 북미의 암치료용 생물학적 제제 시장 분석

제9장 유럽의 암치료용 생물학적 제제 시장 분석

제10장 아시아태평양의 암치료용 생물학적 제제 시장 분석

제11장 라틴아메리카의 암치료용 생물학적 제제 시장 분석

제12장 중동 및 아프리카의 암치료용 생물학적 제제 시장 분석

제13장 기업 개요

  • 경쟁 구도(2022년)
  • 전략 전망
  • AbbVie
  • Amgen
  • Astellas Pharma
  • AstraZeneca PLC
  • Bristol Myers Squibb
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck &Co., Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Ltd

제14장 결론과 추천 사항

  • 결론
  • 시장 진출기업을 위한 추천 사항
LSH 23.07.06

The global Cancer Biologics market was estimated to be valued at US$ 115.9 billion in 2023 and is expected to register a CAGR of 9.1% from 2023 to 2033..

“The Cancer Biologics Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing geriatric population will drive demand for cancer biologics therapy

Rising elderly population is one of the major factors driving the cancer biological therapy market growth. According to United Nation estimates, the global elderly population aged 60 years and above is set to double and reach over 2.1 billion by 2050 from over 962 million in 2017. Geriatric population is at a higher risk of acquiring various types of cancer such as lung cancer, colon cancer and breast cancer boosting the demand for cancer biological therapies. According to the National Center for Biotechnology Information (NCBI), cancer is one of the predominant causes of morbidity and mortality among the geriatric population base. Around 60% of all cancer cases and approximately 70% of cancer-related deaths occur in patients above 65 years of age. Thus, the increasing elderly population base suffering from cancer will propel the demand for cancer biological therapy, thereby fostering business growth.

Toxicity and Adverse Effects associated with Cancer Therapy

Anticancer drugs have severe side effects and its clinical usage for cancer therapy is limited by its toxicity. The adverse effects vary drug to drug for numerous reasons. They may be chronic or acute, mild, permanent, self-limited or potentially life threatening. Common side effects associated with the anti-cancer drugs include low blood counts that increase the possibility of developing infection or anaemia, mouth soreness, tiredness, nausea, loss of appetite, vomiting, constipation or diarrhoea, skin reactions, hair loss, pain or nerve changes. However, certain side effects can have long lasting or permanent effects. For example, certain chemotherapy drugs can result in infertility or the inability to father a child that may be permanent. Additionally, chemotherapy may lead to long-term damage to the lungs, heart, kidneys, and reproductive organs. Growing awareness among patients regarding side effects of cancer treatment may hamper patient preference towards the cancer therapy and can therefore impede the market growth during the coming years.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the Cancer Biologics Market evolving?
  • What is driving and restraining the Cancer Biologics Market?
  • How will each Cancer Biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each Cancer Biologics submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading Cancer Biologics Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Cancer Biologics projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of Cancer Biologics projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Cancer Biologics Market?
  • Where is the Cancer Biologics Market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Cancer Biologics Market today, and over the next 10 years:

  • Our 308-page report provides 117 tables and 187 charts/graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Cancer Biologics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Cancer Biologics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

By Product

  • Monoclonal Antibodies
    • Naked Monoclonal Antibodies
    • Conjugated Monoclonal Antibodies
    • Bispecific Monoclonal Antibodies
  • Vaccines
    • Preventive Vaccines
    • Therapeutic Vaccines
  • Cancer Growth Blockers
    • Tyrosine kinase Inhibitors (TKI)
    • Proteasome Inhibitors (PI)
    • mTOR Inhibitors
  • Blood Cell Growth Factors
    • Lenograstim
    • Filgrastim
  • Cytokine
    • Interferons
    • Interleukins

By Application

  • Non-Small Cell Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Acute Myeloid Leukaemia
  • Lymphoma
  • Multiple Myeloma
  • Ovarian Cancer
  • Colorectal Cancer
  • Gastric Cancers
  • Other Applications

By Route of Administration

  • Oral
  • Injectable

Regional and Country level Market estimates:

North America

  • U.S
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Cancer Biologics Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • AbbVie
  • Amgen
  • Astellas Pharma
  • AstraZeneca PLC
  • Bristol Myers Squibb
  • Eisai Co., Ltd.
  • Eli Lilly and company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc
  • Novartis AG
  • Takeda Pharmaceutical Company

Overall world revenue for Cancer biologics market, 2023 to 2033 in terms of value the market will surpass US$ 115.9 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Cancer biologics market, 2023 to 2033 report help you?

In summary, our 300+ page report provides you with the following knowledge:

  • Revenue forecasts to 2033 for Cancer biologics market, 2023 to 2033 Market, with forecasts for product, application and route of administration, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 16 key national markets - See forecasts for the Cancer biologics market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 11 of the major companies involved in the Cancer biologics market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Cancer biologics market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Cancer Biologics Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Reports
  • 1.10 About

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Increasing Prevalence of Cancer
      • 3.2.1.2 Growing Geriatric Population Susceptible for Cancer
      • 3.2.1.3 Technological Advancements in Cancer Biologics Therapy
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 High Cost of Treatment
      • 3.2.2.2 Toxicity and Adverse Effects of Cancer Biologics Treatment
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Favourable Government Policies
      • 3.2.3.2 Growing Adoption of Immunotherapy
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Cancer Biologics Market Analysis by Product

  • 4.1 Key Findings
  • 4.2 Indication Segment: Market Attractiveness Index
  • 4.3 Cancer Biologics Market Size Estimation and Forecast by Product
  • 4.4 Monoclonal Antibodies
    • 4.4.1 Cancer Biologics Market Size Estimation and Forecast by Monoclonal Antibodies
    • 4.4.2 Market Size by Region, 2023-2033 (US$ Billion)
    • 4.4.3 Market Share by Region, 2023 & 2033 (%)
    • 4.4.4 Naked Monoclonal Antibodies
      • 4.4.4.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.4.4.2 Market Share by Region, 2023 & 2033 (%)
    • 4.4.5 Conjugated Monoclonal Antibodies
      • 4.4.5.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.4.5.2 Market Share by Region, 2023 & 2033 (%)
    • 4.4.6 Bispecific Monoclonal Antibodies
      • 4.4.6.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.4.6.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5 Vaccines
    • 4.5.1 Cancer Biologics Market Size Estimation and Forecast by Vaccines
    • 4.5.2 Market Size by Region, 2023-2033 (US$ Billion)
    • 4.5.3 Market Share by Region, 2023 & 2033 (%)
    • 4.5.4 Preventive Vaccines
      • 4.5.4.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.5.4.2 Market Share by Region, 2023 & 2033 (%)
    • 4.5.5 Therapeutic Vaccines
      • 4.5.5.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.5.5.2 Market Share by Region, 2023 & 2033 (%)
  • 4.6 Cancer Growth Blockers
    • 4.6.1 Cancer Biologics Market Size Estimation and Forecast by Cancer Growth Blockers
    • 4.6.2 Market Size by Region, 2023-2033 (US$ Billion)
    • 4.6.3 Market Share by Region, 2023 & 2033 (%)
    • 4.6.4 Tyrosine Kinase Inhibitors
      • 4.6.4.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.6.4.2 Market Share by Region, 2023 & 2033 (%)
    • 4.6.5 Proteasome Inhibitors (PI)
      • 4.6.5.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.6.5.2 Market Share by Region, 2023 & 2033 (%)
    • 4.6.6 mTOR Inhibitors
      • 4.6.6.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.6.6.2 Market Share by Region, 2023 & 2033 (%)
  • 4.7 Blood Cell Growth Factors
    • 4.7.1 Cancer Biologics Market Size Estimation and Forecast by Blood Cell Growth Factors
    • 4.7.2 Market Size by Region, 2023-2033 (US$ Billion)
    • 4.7.3 Market Share by Region, 2023 & 2033 (%)
    • 4.7.4 Lenograstim
      • 4.7.4.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.7.4.2 Market Share by Region, 2023 & 2033 (%)
    • 4.7.5 Filgrastim
      • 4.7.5.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.7.5.2 Market Share by Region, 2023 & 2033 (%)
  • 4.8 Cytokine
    • 4.8.1 Cancer Biologics Market Size Estimation and Forecast by Cytokine
    • 4.8.2 Market Size by Region, 2023-2033 (US$ Billion)
    • 4.8.3 Market Share by Region, 2023 & 2033 (%)
    • 4.8.4 Interferons
      • 4.8.4.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.8.4.2 Market Share by Region, 2023 & 2033 (%)
    • 4.8.5 Interleukins
      • 4.8.5.1 Market Size by Region, 2023-2033 (US$ Billion)
      • 4.8.5.2 Market Share by Region, 2023 & 2033 (%)

5 Cancer Biologics Market Analysis by Application

  • 5.1 Key Findings
  • 5.2 Indication Segment: Market Attractiveness Index
  • 5.3 Cancer Biologics Market Size Estimation and Forecast by Application
  • 5.4 Non-Small Cell Lung Cancer
    • 5.4.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 5.4.2 Market Share by Region, 2023 & 2033 (%)
  • 5.5 Prostate Cancer
    • 5.5.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 5.5.2 Market Share by Region, 2023 & 2033 (%)
  • 5.6 Breast Cancer
    • 5.6.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 5.6.2 Market Share by Region, 2023 & 2033 (%)
  • 5.7 Acute Myeloid Leukaemia
    • 5.7.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 5.7.2 Market Share by Region, 2023 & 2033 (%)
  • 5.8 Lymphoma
    • 5.8.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 5.8.2 Market Share by Region, 2023 & 2033 (%)
  • 5.9 Multiple Myeloma
    • 5.9.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 5.9.2 Market Share by Region, 2023 & 2033 (%)
  • 5.10 Ovarian Cancer
    • 5.10.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 5.10.2 Market Share by Region, 2023 & 2033 (%)
  • 5.11 Colorectal cancer
    • 5.11.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 5.11.2 Market Share by Region, 2023 & 2033 (%)
  • 5.12 Gastric cancer
    • 5.12.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 5.12.2 Market Share by Region, 2023 & 2033 (%)
  • 5.13 Others
    • 5.13.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 5.13.2 Market Share by Region, 2023 & 2033 (%)

6 Cancer Biologics Market Analysis by Route of Administration

  • 6.1 Key Findings
  • 6.2 Route of Administration Segment: Market Attractiveness Index
  • 6.3 Cancer Biologics Market Size Estimation and Forecast by Route of Administration
  • 6.4 Oral
    • 6.4.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 6.4.2 Market Share by Region, 2023 & 2033 (%)
  • 6.5 Injectable
    • 6.5.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 6.5.2 Market Share by Region, 2023 & 2033 (%)

7 Cancer Biologics Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast

8 North America Cancer Biologics Market Analysis

  • 8.1 Key Findings
  • 8.2 North America Cancer Biologics Market Attractiveness Index
  • 8.3 North America Cancer Biologics Market by Country, 2023, 2028 & 2033 (US$ Billion)
  • 8.4 North America Cancer Biologics Market Size Estimation and Forecast by Country
  • 8.5 North America Cancer Biologics Market Size Estimation and Forecast by Product
  • 8.6 North America Cancer Biologics Market Size Estimation and Forecast by Application
  • 8.7 North America Cancer Biologics Market Size Estimation and Forecast by Route of Administration
  • 8.8 U.S. Cancer Biologics Market Analysis
  • 8.9 Canada Cancer Biologics Market Analysis

9 Europe Cancer Biologics Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe Cancer Biologics Market Attractiveness Index
  • 9.3 Europe Cancer Biologics Market by Country, 2023, 2028 & 2033 (US$ Billion)
  • 9.4 Europe Cancer Biologics Market Size Estimation and Forecast by Country
  • 9.5 Europe Cancer Biologics Market Size Estimation and Forecast by Product
  • 9.6 Europe Cancer Biologics Market Size Estimation and Forecast by Application
  • 9.7 Europe Cancer Biologics Market Size Estimation and Forecast by Route of Administration
  • 9.8 Germany Cancer Biologics Market Analysis
  • 9.9 France Cancer Biologics Market Analysis
  • 9.10 UK Cancer Biologics Market Analysis
  • 9.11 Italy Cancer Biologics Market Analysis
  • 9.12 Spain Cancer Biologics Market Analysis
  • 9.13 Russia Cancer Biologics Market Analysis
  • 9.14 Rest of Europe Cancer Biologics Market Analysis

10 Asia Pacific Cancer Biologics Market Analysis

  • 10.1 Key Findings
  • 10.2 Asia Pacific Cancer Biologics Market Attractiveness Index
  • 10.3 Asia Pacific Cancer Biologics Market by Country, 2023, 2028 & 2033 (US$ Billion)
  • 10.4 Asia Pacific Cancer Biologics Market Size Estimation and Forecast by Country
  • 10.5 Asia Pacific Cancer Biologics Market Size Estimation and Forecast by Product
  • 10.6 Asia Pacific Cancer Biologics Market Size Estimation and Forecast by Application
  • 10.7 Asia Pacific Cancer Biologics Market Size Estimation and Forecast by Route of Administration
  • 10.8 Japan Cancer Biologics Market Analysis
  • 10.9 China Cancer Biologics Market Analysis
  • 10.10 India Cancer Biologics Market Analysis
  • 10.11 Australia Cancer Biologics Market Analysis
  • 10.12 South Korea Cancer Biologics Market Analysis
  • 10.13 Rest of Asia Pacific Cancer Biologics Market Analysis

11 Latin America Cancer Biologics Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America Cancer Biologics Market Attractiveness Index
  • 11.3 Latin America Cancer Biologics Market by Country, 2023, 2028 & 2033 (US$ Billion)
  • 11.4 Latin America Cancer Biologics Market Size Estimation and Forecast by Country
  • 11.5 Latin America Cancer Biologics Market Size Estimation and Forecast by Product
  • 11.6 Latin America Cancer Biologics Market Size Estimation and Forecast by Application
  • 11.7 Latin America Cancer Biologics Market Size Estimation and Forecast by Route of Administration
  • 11.8 Brazil Cancer Biologics Market Analysis
  • 11.9 Mexico Cancer Biologics Market Analysis
  • 11.10 Rest of Latin America Cancer Biologics Market Analysis

12 MEA Cancer Biologics Market Analysis

  • 12.1 Key Findings
  • 12.2 MEA Cancer Biologics Market Attractiveness Index
  • 12.3 MEA Cancer Biologics Market by Country, 2023, 2028 & 2033 (US$ Billion)
  • 12.4 MEA Cancer Biologics Market Size Estimation and Forecast by Country
  • 12.5 MEA Cancer Biologics Market Size Estimation and Forecast by Product
  • 12.6 MEA Cancer Biologics Market Size Estimation and Forecast by Application
  • 12.7 MEA Cancer Biologics Market Size Estimation and Forecast by Route of Administration
  • 12.8 GCC Cancer Biologics Market Analysis
  • 12.9 South Africa Cancer Biologics Market Analysis
  • 12.10 Rest of MEA Cancer Biologics Market Analysis

13 Company Profiles

  • 13.1 Competitive Landscape, 2022
  • 13.2 Strategic Outlook
  • 13.3 AbbVie
    • 13.3.1 Company Snapshot
    • 13.3.2 Company Overview
    • 13.3.3 Financial Analysis
      • 13.3.3.1 Net Revenue, 2017-2022
      • 13.3.3.2 R&D, 2017-2022
      • 13.3.3.3 Regional Market Shares, 2022
    • 13.3.4 Product Benchmarking
    • 13.3.5 Strategic Outlook
  • 13.4 Amgen
    • 13.4.1 Company Snapshot
    • 13.4.2 Company Overview
    • 13.4.3 Financial Analysis
      • 13.4.3.1 Net Revenue, 2017-2022
      • 13.4.3.2 R&D, 2017-2022
      • 13.4.3.3 Regional Market Shares, 2022
    • 13.4.4 Product Benchmarking
    • 13.4.5 Strategic Outlook
  • 13.5 Astellas Pharma
    • 13.5.1 Company Snapshot
    • 13.5.2 Company Overview
    • 13.5.3 Financial Analysis
      • 13.5.3.1 Net Revenue, 2017-2022
      • 13.5.3.2 R&D, 2017-2022
      • 13.5.3.3 Regional Market Shares, 2022
    • 13.5.4 Product Benchmarking
    • 13.5.5 Strategic Outlook
  • 13.6 AstraZeneca PLC
    • 13.6.1 Company Snapshot
    • 13.6.2 Company Overview
    • 13.6.3 Financial Analysis
      • 13.6.3.1 Net Revenue, 2017-2022
      • 13.6.3.2 R&D, 2017-2022
      • 13.6.3.3 Regional Market Shares, 2022
    • 13.6.4 Product Benchmarking
    • 13.6.5 Strategic Outlook
  • 13.7 Bristol Myers Squibb
    • 13.7.1 Company Snapshot
    • 13.7.2 Company Overviews
    • 13.7.3 Financial Analysis
      • 13.7.3.1 Net Revenue, 2017-2022
      • 13.7.3.2 R&D, 2017-2022
      • 13.7.3.3 Regional Market Shares, 2022
    • 13.7.4 Product Benchmarking
    • 13.7.5 Strategic Outlook
  • 13.8 Eisai Co., Ltd
    • 13.8.1 Company Snapshot
    • 13.8.2 Company Overview
    • 13.8.3 Financial Analysis
      • 13.8.3.1 Net Revenue, 2017-2022
      • 13.8.3.2 R&D, 2017-2022
      • 13.8.3.3 Regional Market Shares, 2022
    • 13.8.4 Product Benchmarking
    • 13.8.5 Strategic Outlook
  • 13.9 Eli Lilly and Company
    • 13.9.1 Company Snapshot
    • 13.9.2 Company Overview
    • 13.9.3 Financial Analysis
      • 13.9.3.1 Net Revenue, 2017-2022
      • 13.9.3.2 R&D, 2017-2022
      • 13.9.3.3 Regional Market Shares, 2022
    • 13.9.4 Product Benchmarking
    • 13.9.5 Strategic Outlook
  • 13.10 F. Hoffmann-La Roche Ltd
    • 13.10.1 Company Snapshot
    • 13.10.2 Company Overview
    • 13.10.3 Financial Analysis
      • 13.10.3.1 Net Revenue, 2017-2022
      • 13.10.3.2 R&D, 2017-2022
      • 13.10.3.3 Regional Market Shares, 2022
    • 13.10.4 Product Benchmarking
    • 13.10.5 Strategic Outlook
  • 13.11 Merck & Co., Inc.
    • 13.11.1 Company Snapshot
    • 13.11.2 Company Overview
    • 13.11.3 Financial Analysis
      • 13.11.3.1 Net Revenue, 2017-2022
      • 13.11.3.2 R&D, 2017-2022
      • 13.11.3.3 Regional Market Shares, 2022
    • 13.11.4 Product Benchmarking
    • 13.11.5 Strategic Outlook
  • 13.12 Novartis AG
    • 13.12.1 Company Snapshot
    • 13.12.2 Company Overview
    • 13.12.3 Financial Analysis
      • 13.12.3.1 Net Revenue, 2017-2022
      • 13.12.3.2 R&D, 2017-2022
      • 13.12.3.3 Regional Market Shares, 2022
    • 13.12.4 Product Benchmarking
    • 13.12.5 Strategic Outlook
  • 13.13 Takeda Pharmaceutical Company Ltd
    • 13.13.1 Company Snapshot
    • 13.13.2 Company Overview
    • 13.13.3 Financial Analysis
      • 13.13.3.1 Net Revenue, 2017-2022
      • 13.13.3.2 R&D, 2017-2022
      • 13.13.3.3 Regional Market Shares, 2022
    • 13.13.4 Product Benchmarking
    • 13.13.5 Strategic Outlook

14 Conclusion and Recommendations

  • 14.1 Concluding Remarks from
  • 14.2 Recommendations for Market Players
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제